Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
179
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 44 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 27, 2001 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as UNITRON PEG (DIN 02242969) under ATC L03AB10 PEGINTERFERON ALFA-2B. Indications are not published in the Drug Product… | DIN02242969 | withdrawnsource: Cancelled Post Marketsince Feb 1, 2012 | health-canada-dpd |
| Mar 27, 2001 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as UNITRON PEG (DIN 02242968) under ATC L03AB10 PEGINTERFERON ALFA-2B. Indications are not published in the Drug Product… | DIN02242968 | withdrawnsource: Cancelled Post Marketsince Feb 1, 2012 | health-canada-dpd |
| Mar 27, 2001 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as UNITRON PEG (DIN 02242967) under ATC L03AB10 PEGINTERFERON ALFA-2B. Indications are not published in the Drug Product… | DIN02242967 | withdrawnsource: Cancelled Post Marketsince Feb 1, 2012 | health-canada-dpd |
| Mar 27, 2001 | Peginterferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as UNITRON PEG (DIN 02242966) under ATC L03AB10 PEGINTERFERON ALFA-2B. Indications are not published in the Drug Product… | DIN02242966 | withdrawnsource: Cancelled Post Marketsince Feb 1, 2012 | health-canada-dpd |
| Mar 20, 2001 | Ifosfamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as IFEX (DIN 02241357) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug Product Database — see… | DIN02241357 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 22, 2001 | Hydroxyurea | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYLAN-HYDROXYUREA (DIN 02242920) under ATC L01XX05 HYDROXYCARBAMIDE. Indications are not published in the Drug… | DIN02242920 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 25, 2001 | Ifosfamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as IFEX (DIN 02241356) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug Product Database — see… | DIN02241356 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 29, 2000 | Cytarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as DEPOCYT (DIN 02241150) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see… | DIN02241150 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 26, 2000 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PROCYTOX (DIN 02241797) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product… | DIN02241797 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 26, 2000 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PROCYTOX (DIN 02241798) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product… | DIN02241798 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 1, 2000 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PROCYTOX (DIN 02241795) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product… | DIN02241795 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 22, 2000 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as PROCYTOX (DIN 02241796) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in the Drug Product… | DIN02241796 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 4, 2000 | Dacarbazine | Health Canada CA | cancer not stated in this record | Marketed in Canada as DACARBAZINE FOR INJECTION BP (DIN 02241445) under ATC L01AX04 DACARBAZINE. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 20, 2000 | Rituximab | Health Canada CA | cancer not stated in this record | Marketed in Canada as RITUXAN (DIN 02241927) under ATC L01FA01 RITUXIMAB. Indications are not published in the Drug Product Database — see… | DIN02241927 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 24, 2000 | Buserelin | Health Canada CA | cancer not stated in this record | Marketed in Canada as SUPREFACT DEPOT 3 MONTHS (DIN 02240749) under ATC L02AE01 BUSERELIN. Indications are not published in the Drug… | DIN02240749 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 28, 1999 | Etoposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ETOPOSIDE INJECTION, USP (DIN 02241182) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug… | DIN02241182 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 1999 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEMODAL (DIN 02241096) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database —… | DIN02241096 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 28, 1999 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAMOXIFEN (DIN 02237597) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database —… | DIN02237597 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 23, 1999 | Trastuzumab | Health Canada CA | cancer not stated in this record | Marketed in Canada as HERCEPTIN (DIN 02240692) under ATC L01FD01 TRASTUZUMAB. Indications are not published in the Drug Product Database —… | DIN02240692 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 12, 1999 | Interferon Alfacon-1 | Health Canada CA | cancer not stated in this record | Marketed in Canada as INFERGEN (DIN 02239832) under ATC L03AB09 INTERFERON ALFACON-1. Indications are not published in the Drug Product… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 31, 1999 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as REBETRON READY TO USE SOLUTION (ALBUMIN(HUMAN)FREE) (6000000 IU/ML AND 200MG CAPSULES) (DIN 02239730) under ATC… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 22, 1999 | Flutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUTAMIDE-250 (DIN 02239388) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database… | DIN02239388 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 31, 1998 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as INTRON A - KIT (PWS+DILUENT) 5000000IU/VIAL (DIN 02223392) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 25, 1998 | Fluorouracil | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUOROURACIL INJECTION USP (DIN 02182742) under ATC L01BC02 FLUOROURACIL. Indications are not published in the Drug… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 13, 1998 | Pegaspargase | Health Canada CA | cancer not stated in this record | Marketed in Canada as ONCASPAR (DIN 02236849) under ATC L01XX24 PEGASPARGASE. Indications are not published in the Drug Product Database —… | DIN02236849 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 10, 1998 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as XELODA (DIN 02238454) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product Database —… | DIN02238454 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 19, 1998 | Doxorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAELYX (DIN 02238389) under ATC L01DB01 DOXORUBICIN. Indications are not published in the Drug Product Database — see… | DIN02238389 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 15, 1998 | Mitomycin | Health Canada CA | cancer not stated in this record | Marketed in Canada as MITOMYCIN FOR INJECTION USP (DIN 02237745) under ATC L01DC03 MITOMYCIN. Indications are not published in the Drug… | DIN02237745 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 19, 1998 | Interferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as AVONEX (DIN 02237770) under ATC L03AB07 INTERFERON BETA-1A. Indications are not published in the Drug Product… | DIN02237770 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jun 29, 2017 |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 17, 2000 | Exemestane | Health Canada CA | cancer not stated in this record | Marketed in Canada as AROMASIN (DIN 02242705) under ATC L02BG06 EXEMESTANE. Indications are not published in the Drug Product Database —… | DIN02242705 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Dormantsince Oct 13, 2024 |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jan 17, 2019 |
| health-canada-dpd |
| Dec 23, 1999 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as REBETRON SOLUTION (ALBUMIN (HUMAN) FREE) (18 MIU MULTI-DOSE PEN / 200MG CAPSULES) (DIN 02241159) under ATC L03AB60… | DIN02241159 | withdrawnsource: Cancelled Post Marketsince Oct 27, 2004 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 12, 1999 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEMODAL (DIN 02241095) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database —… | DIN02241095 | approvedsource: Marketed | health-canada-dpd |
| Nov 12, 1999 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEMODAL (DIN 02241094) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database —… | DIN02241094 | approvedsource: Marketed | health-canada-dpd |
| Nov 12, 1999 | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEMODAL (DIN 02241093) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database —… | DIN02241093 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Oct 25, 2016 |
| health-canada-dpd |
| Sep 28, 1999 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as TAMOXIFEN (DIN 02237596) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database —… | DIN02237596 | withdrawnsource: Cancelled Post Marketsince Oct 25, 2016 | health-canada-dpd |
| Sep 23, 1999 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as INTRON A (DIN 02240695) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not published in the Drug Product… | DIN02240695 | withdrawnsource: Cancelled Post Marketsince Dec 14, 2018 | health-canada-dpd |
| Sep 23, 1999 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as INTRON A (DIN 02240694) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not published in the Drug Product… | DIN02240694 | withdrawnsource: Cancelled Post Marketsince Feb 20, 2019 | health-canada-dpd |
| Sep 23, 1999 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as INTRON A (DIN 02240693) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not published in the Drug Product… | DIN02240693 | withdrawnsource: Cancelled Post Marketsince Dec 20, 2018 | health-canada-dpd |
| Sep 23, 1999 | Busulfan | Health Canada CA | cancer not stated in this record | Marketed in Canada as BUSULFEX (DIN 02240602) under ATC L01AB01 BUSULFAN. Indications are not published in the Drug Product Database — see… | DIN02240602 | withdrawnsource: Cancelled Post Marketsince Sep 1, 2020 | health-canada-dpd |
| Sep 17, 1999 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-METHOTREXATE (DIN 02182963) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug Product… | DIN02182963 | approvedsource: Marketed | health-canada-dpd |
| Sep 13, 1999 | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUPRON DEPOT (DIN 02239834) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database… | DIN02239834 | approvedsource: Marketed | health-canada-dpd |
| Sep 13, 1999 | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as LUPRON DEPOT (DIN 02239833) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database… | DIN02239833 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Oct 31, 2012 |
| health-canada-dpd |
| DIN02239730 |
| withdrawnsource: Cancelled Post Marketsince Oct 27, 2004 |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 23, 2009 |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jul 11, 2000 |
| health-canada-dpd |
| Dec 10, 1998 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as INTRON A (DIN 02238675) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not published in the Drug Product… | DIN02238675 | withdrawnsource: Cancelled Post Marketsince Apr 12, 2021 | health-canada-dpd |
| Dec 10, 1998 | Interferon Alfa-2b | Health Canada CA | cancer not stated in this record | Marketed in Canada as INTRON A (DIN 02238674) under ATC L03AB05 INTERFERON ALFA-2B. Indications are not published in the Drug Product… | DIN02238674 | withdrawnsource: Cancelled Post Marketsince Aug 31, 2021 | health-canada-dpd |
| Dec 1, 1998 | Flutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUTAMIDE (DIN 02239045) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database —… | DIN02239045 | withdrawnsource: Cancelled Post Marketsince Oct 25, 2016 | health-canada-dpd |
| Dec 1, 1998 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-TAMOXIFEN (DIN 02237460) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database… | DIN02237460 | withdrawnsource: Cancelled Post Marketsince Oct 28, 2016 | health-canada-dpd |
| Dec 1, 1998 | Tamoxifen | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-TAMOXIFEN (DIN 02237459) under ATC L02BA01 TAMOXIFEN. Indications are not published in the Drug Product Database… | DIN02237459 | withdrawnsource: Cancelled Post Marketsince Oct 28, 2016 | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Nov 27, 2020 |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Jan 2, 2004 |
| health-canada-dpd |
| Oct 8, 1998 | Flutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUTAMIDE (DIN 02238560) under ATC L02BB01 FLUTAMIDE. Indications are not published in the Drug Product Database —… | DIN02238560 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Dec 7, 2022 |
| health-canada-dpd |
| Sep 10, 1998 | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as XELODA (DIN 02238453) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product Database —… | DIN02238453 | withdrawnsource: Cancelled Post Marketsince Dec 7, 2022 | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Feb 28, 2020 |
| health-canada-dpd |
| Jul 13, 1998 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION USP (DIN 02182955) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02182955 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Oct 30, 2010 |
| health-canada-dpd |